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A B S T R A C T
Febrile neutropenia is a common complication of antineoplasic chemotherapy. It is 
a potentially serious event, sometimes lethal. However, it is well recognized that the 
population of patients with febrile neutropenia is heterogeneous in terms of progno-
sis. Simplified therapy, for instance oral antibiotic empiric treatment or ambulatory 
treatment, in comparison to the classical management of intravenously administered 
empiric antibiotics and in-hospital surveillance, has been the purpose of research for 
patients predicted at low-risk for serious complications development. However, for such 
a strategy to be successful an accurate identification of patients at low-risk is required. 
The objective of the present review is to present the available tools for risk assessment, 
in adult patients populations and to review the status of our knowledge regarding the 
efficacy and the safety of risk-adapted therapy.
I N T R O D U C T I O N
Febrile neutropenia in cancer patients is a common complication of antineoplasic 
chemotherapy. It is a potentially serious event, sometimes lethal, although many patients 
respond quickly to broad spectrum empiric treatment with an indolent course of the 
febrile neutropenic episode. However, others will develop severe complications and 
2% to 10% will even die before resolution of the episode. Febrile neutropenia is also 
associated with added morbidity, represents increased costs of anticancer treatments 
and can jeopardize patients quality of life.
Some preventive measures, like the use of colony-stimulating factors, may be ef-
fective, but due to cost-effectiveness issues, have to be restricted to selected patients 
at high risk of developing severe neutropenia and/or febrile neutropenia [1,2]. The 
use of prophylactic antibiotics is controversial because it may induce emergence of 
resistant pathogens and does not have any clear impact on mortality [3].
The classical approach at the onset of febrile neutropenia, has been to start empiric 
broad-spectrum treatment given in a hospital environment [4]. However, as fever and 
neutropenia resolve quite quickly in many patients without any further complication, 
it has been recognized, for more than two decades, that febrile neutropenia is quite 
a heterogeneous syndrome leading to the need to be able to identify the patients who 
will go well and recover quickly following the administration of the empiric treatment. 
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Provided we are able to distinguish at least two populations 
of patients, one at low-risk and one at high-risk, it is possible 
to look at simplified therapeutic management of low-risk pa-
tients. In this review, we will then try to answer the following 
two questions: a) what are the available tools for identifying 
low-risk patients ? b) How can therapy be safely adapted and 
simplified for low-risk patients? As populations of adult patients 
and children are studied separately for such obvious reasons as 
differences in underlying disease, in etiology of infections and 
of type of complications susceptible to occur, we will restrict 
our presentation to populations of adult patients.
W h A T  A R E  T h E  AVA I l A B l E  T O O l S  f O R 
I D E N T I f y I N g  l O W - R I S K  pA T I E N T S ?
Essentially, two approaches are available for selecting a 
population of patients at low-risk. The first one is to rely on a 
set of predictive factors published in the literature or chosen 
on the basis of clinical expertise without analyzing the interac-
tion between them but rather combining them empirically. The 
advantage of this approach is that the definition of low-risk may 
be changed very easily depending on the context of use and on 
the occurrence of new studies’ results. The disadvantage is that 
it is very difficult to assess the performance of the definition 
in terms of sensitivity, specificity and positive and negative 
predictive values. The following factors are often considered 
to delineate low-risk: absence of hemodynamic instability, 
absence of hypotension, no altered mental status, no respira-
tory failure, no renal failure, no abnormal hepatic tests, good 
clinical condition, an expected short duration of neutropenia, 
no acute leukaemia, no bone marrow or peripheral blood stem 
cell transplant, absence of chills, no abnormal chest X-ray, no 
cellulitis or signs of focal infection, no catheter-related infec-
tion, no need for intravenous supportive therapy [5-9]. This 
was the most frequently adopted methodology for the clinical 
trials which tested oral antibiotic regimens as an alternative 
for patients considered at low-risk. 
The second, more recent approach is to try to develop 
validated models integrating several factors in a well-defined 
way and considering their independent value or their interac-
tions. Models have first to be developed and then tested on a 
separate patients population in order to be certain that they are 
well calibrated (predicted outcomes have to match observed 
outcomes) and reliably transportable in other settings (to 
other institutions for instance); alternatively, cross-validation 
techniques may be used. Their discrimination ability also has 
to be regularly monitored. Advantages are that such an as-
sessment of low-risk is standardized and more objective and 
that the classification has known properties. The method is 
also more parsimonious with the use of independent only 
predictive factors. The predicted outcome is also more care-
fully defined. However, the development process is long; the 
need for validation should not be underestimated and the 
context of use has to be considered before introducing them 
in clinical practice.
To our knowledge, for populations of adult patients, two 
scoring systems have been developed and validated: the Talcott 
model and the MASCC score. Both use the same endpoint: 
the occurrence of serious medical complications (and not the 
response to empiric treatment). The choice of this endpoint 
was stressed as a progress in the discussion of risk assessment 
[10] although the definition of a serious medical complication, 
presented in Table 1, may appear somehow arbitrary. Indeed, 
the need to change empiric treatment does not necessarily 
mean that the clinical course of the patient will not be benign 
and is felt as less adequate in estimating the risk associated 
to groups of patients.
T h E  T A l C O T T  m O D E l  :
Talcott and colleagues were the first to define a classification 
of patients into four groups (Table 2), the so-called group IV 
(patients out of the hospital at fever onset, with cancer con-
TABlE 1. Medical complications considered as serious as 
defined in [13]
Hypotension (defined as systolic blood pressure <90 mm Hg or 
the need for pressor support to maintain blood pressure)
•
Respiratory failure (defined as arterial oxygen pressure less than 
60 mm Hg while breathing room air or need for mechanical 
ventilation
•
Intensive care unit admission•
Disseminated intravascular coagulation•
Confusion or altered mental state•
Congestive cardiac failure seen on chest X-ray and requiring 
treatment
•
Bleeding severe enough to require transfusion•
Arrhythmia or ECG changes requiring treatment•
Renal failure requiring investigation and/or treatment with 
intravenous fluids, dialysis or any other intervention
•
Other complication judged serious and clinically significant by 
the investigator
•
TABlE 2. The Talcott’s classification
Group I Inpatients (at the time of fever onset)
Group II Outpatients with acute comorbidity requiring by 
itself hospitalisation
Group III Outpatients without comorbidity but with 
uncontrolled cancer
Group IV Outpatients with cancer controlled and without 
comorbidity
Comment: Groupe IV is considered to be at low-risk, there is no 
constructed ordering for groups I to III.
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trolled and without comorbidity) was considered as a low-risk 
group [11]. Groups were constructed using clinical arguments 
and expertise and, at a first stage, tested on a retrospective 
series of 261 patients from a single institution. It was further 
validated on a prospective series of 444 patients managed at 
two institutions [12]. 
T h E  m A S C C  S C O R E :
The second model was developed thanks to an international 
prospective study conducted by the Multinational Association 
for Supportive Care in Cancer (MASCC) [13]. The study 
population was divided into two parts: one for derivation of 
the score, the so-called MASCC score based on multivariate 
logistic regression models (n=756) and one for validating it 
(n=383). A numeric risk-index score was constructed weight-
ing seven independent characteristics shown to be associated 
with a higher probability of favourable outcome. The score 
is presented in Table 3; it ranges from 0 to 26 and a score 
higher or equal to 21 was defined as predicting low-risk for 
complication. This threshold was chosen targeting, in the 
derivation set, a rate of complications of 5%, as a compromise 
between positive predictive value and sensitivity of the clinical 
prediction rule. The characteristics of both models, Talcott’s 
and MASCC, on the validation set used in Klastersky[13] 
are shown in Table 4. So, Klastersky’s publication [13] can be 
seen as a further validation of the Talcott score. Comparing 
the characteristics of the prediction rules, the MASCC score 
constituted an improvement of the sensitivity and of the overall 
misclassification rate. On the other hand, the positive predictive 
value might be lower, at least when the threshold of 21 is used. 
Increasing the threshold might be a way to increase positive 
predictive value but will also reduce the improvement in the 
sensitivity of the model.
The MASCC score was then validated on new series. uys et 
al [14] studied prospectively 80 episodes of febrile neutropenia, 
occurring mostly in patients with solid tumor; 58 of them were 
classified as low-risk (score 21), only 1 developing a serious 
complication. Twenty-two episodes were considered as high-
risk. Although 11 patients recovered without complication, 8 
deaths were observed in that subgroup.
A second multicentric study, initiated by the MASCC 
study section on infectious diseases, also prospectively vali-
dated the score, although more than half of the patients were 
registered by a single institution. One thousand and three first 
eligible episodes were studied [15], 549 occurring in patients 
with haematological tumor and 454 in solid tumor patients. 
Overall, 72% of the episodes were classified as low-risk with 
a positive predictive value of 88% (for a sensitivity of 79% 
and a misclassification rate of 26%). In solid tumor patients, 
positive predictive value was 93% while it was decreased to 
84% in haematological malignancies. we should emphasize 
that the underlying disease is not integrated in the score 
although it can be considered as a surrogate for neutropenia 
duration. Some further research might be specially indicated in 
haematological malignancies and the lower positive predictive 
value in that subgroup might be an issue when using the score 
as an element of the therapeutic decision, as will be discussed 
later. That scoring system is presently recommended by the 
IDSA guidelines as a valuable tool for identifying low-risk 
patients [4].
Other endpoints have been considered, namely bacter-
emia or serious (also named invasive or significant) bacterial 
infection [10], most often in populations of children which are 
not the focus of the present review. By doing so, the outcome 
is chosen as a surrogate of an infection susceptible to lead 
more frequently to adverse outcome. The adequacy of that 
endpoint might be different in children and in adults. One 
disadvantage is that some documented infections might be no 
TABlE 4. Characteristics of the clinical prediction rules derived from Talcott’s and MASCC classifications – Validation 
set from [13] (n=383 patients)
group Sensitivity Specificity ppV NpV miscl
Talcott’s group IV 0.30 0.90 0.93 0.23 0.59
MASCC 21 0.71 0.68 0.91 0.36 0.30
PPV=positive predictive value;  NPV=negative predictive value
TABlE 3. The MASCC risk-index
Characteristic Weight
Burden of illness (ie febrile neutropenia):





No chronic obstructive pulmonary disease 4
Solid tumor or no previous fungal infection 4
No dehydration 3
Outpatient status 3
Age <60 years 2
The score is obtained by summing up the different weights (the weights 
for burden of illness are not cumulative) and ranges from 0 to 26. 
Patients with a score 21 are considered at low-risk.
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more associated with complications than fevers of unknown 
origin; furthermore, the impact of identifying patients at risk 
for such an endpoint may not have as direct implications on 
the management of the patients as does the prediction of the 
occurrence of a serious medical complication [10]. 
h O W  C A N  T h E R A p y  B E  A D A p T E D  A N D 
S I m p l I f I E D  f O R  l O W - R I S K  pA T I E N T S ? 
Several approaches can be considered as alternatives to the 
classical approach (hospitalisation and intravenous broad-spec-
trum empiric antibiotic treatment) with two key elements: oral 
antibiotics and outpatient treatment. Simplified management 
can then include early shift from intravenous therapy to oral 
therapy, upfront oral therapy, early discharge under intravenous 
or oral therapy or full outpatient management. 
O R A l  T R E A T m E N T  O R  E A R ly  S W I T C h  f R O m 
I N T R AV E N O U S  T O  O R A l  T R E A T m E N T
The feasibility of oral therapy has been extensively studied. 
Already in 1991, French investigators studied self-adminis-
tration of oral pefloxacin/amoxicillin-clavulanic acid in 68 
febrile episodes occurring after chemotherapy in lymphoma 
outpatients. Although one death was observed, there was no 
need for hospitalisation in more than 80% of the episodes 
[16]. After that study, which, however, directly evaluated 
oral treatment in outpatients without any intermediate step, 
there were several randomised studies addressing the issue 
of the success rate of oral treatment (sometimes with short 
intravenous therapy preceding a switch to oral) compared 
to that of intravenous treatment. Indeed, we believe that the 
question of efficacy of an oral regimen is something different 
than the possibility to treat patients as outpatients. Eligibility 
criteria for oral therapy are somewhat different than those 
that can be considered for ambulatory management. In the 
second situation, many aspects have to be taken into account 
including psychosocial conditions and home environment in 
addition to classical criteria allowing for an oral medication (no 
nausea and no vomiting, ability to swallow, …). These various 
trials looking at efficacy of oral treatment were reviewed in a 
meta-analysis [7]. Fifteen trials were included in the systematic 
review, and all based their assessment of low-risk on clinical 
criteria. In ten trials, the oral arm was a pure one while in 5, a 
sequential approach (intravenous followed by oral) was used. 
The oral treatment consisted of a quinolone only in 6 trials, a 
quinolone in combination with another oral agent in 7 and of 
cefexime in 2. The aggregation of the results led to the conclu-
sion that the response rate to oral therapy is as good as the one 
obtained with intravenous treatment with a relative risk for 
treatment failure of 0.96 (95% CI from 0.84 to 1.11) in favour 
of the oral arm. Observed mortality was also lower with the 
oral regimen, with a relative risk of 0.83 (95% CI: 0.49-1.40). 
However, although the conclusion about efficacy is somewhat 
straightforward and accurate enough to be convincing, the 
confidence intervals remain large for mortality and it is not 
legitimate to conclude that there is no difference.,Nevertheless, 
with the present accumulation of data, there is no reason to 
have concerns about mortality.
The main message from the trials as well as from the reviews 
and meta-analysis is that oral treatment is a safe alternative in 
selected low-risk patients although we do not know from these 
reports how to optimally select low-risk patients as there was 
heterogeneity in the selection criteria.
O U T pA T I E N T  T R E A T m E N T
This issue is much more critical and has been less extensively 
studied and less often by using a randomised design. Although 
some investigators at the MD Anderson Cancer Center have 
acquired a long and successful experience of outpatient man-
agement [17,18], many authors [19,20] expressed the opinion, 
at the time oral treatment was convincingly shown as effective, 
that oral treatment and ambulatory management are two very 
different issues and that careful assessment of risk but also of 
patients’ other conditions (like compliance to treatment and 
home environment) has to be made before sending a patient 
back home together with an adequate and efficient algorithm 
for monitoring the patient once he is at home. This last point 
appears to us very important as the possibility for adequately 
monitoring a patient outside of hospital may be varying in 
different types of institutions. Below we will review some 
studies having addressed the question of oral therapy in an 
outpatient setting. 
In 1994, Talcott published a pilot study of home therapy 
(after two days in hospital) for patients, using his validated 
prediction rule as a guide for therapeutic management. This 
trial was intended to be a preliminary step before a randomised 
study. However, out of the 30 patients, admission was required 
in 9 (30%), a rate that must be considered as too high even if 
not all patients readmitted developed a serious complication 
[21]. The subsequent randomised study suffered from some 
difficulties in accrual but the situation appears to be improved 
[22]. In 1995, Malik et al [23] reported the results on 182 febrile 
neutropenic episodes considered at low-risk (although some 
occurred in acute leukaemic patients, a fact which might not 
be acceptable by all ) randomised between an oral outpatient 
treatment versus an in-hospital intravenous treatment. Response 
rates were similar in the two arms but, in the patients treated 
at home, the need for hospitalisation was 21% with a mortal-
ity rate of 4%, leading to some concerns about the safety of 
the approach. we already mentioned the experience from the 
MD Anderson Cancer Center using both intravenous and oral 
regimens in the outpatient setting with satisfactory success 
rates and low need for hospitalisation. The last published 
experience from that institution was in 2006 [24] and addressed, 
in a pilot study, the feasibility of using an empiric, oral outpa-
tient quinolone monotherapy, gatifloxacin. As the authors 
noted, the MASCC score was not yet published at the time 
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low-risk [27]. Low-risk prediction was, however, comple-
mented by additional criteria (some of them to assess suitabi-
lility of oral treatment with ciprofloxacin and amoxicillin-
clavulanate: absence of antibiotic prophylaxis, absence of 
nausea and vomiting and others to assess psychosocial condi-
tions and home environment). Early discharge was allowed 
whenever possible but was not required by the protocol. All 
febrile neutropenic episodes were screened, 611 during the 
study period, 441 predicted at low-risk and 189 eligible for 
oral therapy (main reason of exclusion was administration of 
prophylactic fluoroquinolones, most often to patients with 
haematological malignancies) in 178 patients. The 178 first 
episodes constituted the group studied for the primary analy-
sis. Seventy-nine patients (44%) benefited from early discharge, 
three had to be readmitted but none of them presented a seri-
ous complication. The overall strategy success was then 95% 
(95% CI: 92%-100%). Among the 99 remaining patients, 9 
developed a serious medical complication including 2 patients 
who died before resolution of the episode; the overall rate of 
resolution without serious complication was 91% (95% CI: 
85%-97%), with an improved rate of 96% when no clear 
medical reason for prolonged hospitalisation was present 
whereas it was only 79% in the reverse situation. This study 
showed that adapted treatment is feasible for predicted low-
risk patients on the basis of the MASCC score. However, 
low-risk prediction and suitability for oral ambulatory treat-
ment are different issues and the proportion of patients fully 
benefited from the adapted approach can not be considered 
very high leading to the conclusion that more efforts are 
needed to identify the right patients suitable for home thera-
py. In any case, it was possible to manage a subgroup of patients 
under conditions of reduced cost and probably improving the 
patients quality of life. Another recently published study [28] 
tested the usefulness of the MASCC score with a similar 
design but included only patients with haematological malig-
nancies. The objective of the trial was to study the feasibility 
and safety of early discharge of low-risk patients 24 hours 
after defervescence with a switch from intravenous to oral 
therapy. They followed 279 episodes of febrile neutropenia in 
191 patients, 105 (38%) predicted by the MASCC score as 
low-risk and 174 as high-risk; about half of these episodes 
occurred in patients with acute leukaemia and another 30% 
in non Hodgkin’s lymphoma patients. Serious medical com-
plications occurred in 63% of high-risk episodes and 15% of 
low-risk episodes (p<0.0001) for an overall misclassification 
of 28%; modifications of the initial antibiotic therapy were 
required more often in patients predicted as high-risk. This 
validates the discriminant value of the score at a threshold of 
21 but also confirms its lower positive predictive value in 
haematological patients (85%). Among the predicted as low-
risk patients, 38 were ineligible for a switch to oral therapy, 
for various reasons, including documentation of infection, 
clinical deterioration, swallowing problems or in a few cases 
they designed the study and they used the Talcott criteria for 
defining low-risk. They also restricted the underlying disease 
to breast cancer or sarcoma as in their experience, these two 
types of tumors constitute more than 90% of their low-risk 
criteria. To further reduce the risk, they excluded patients with 
any focus of infection or impaired renal/hepatic functions. 
Regarding the eligibility of the patient to be treated with 
gatifloxacin, they required no known allergy to any fluoroqui-
nolone and the absence of mucositis of grade 2. Fourty patients 
were included (36 had low-risk prediction by the MASCC 
score). Thirty-eight patients responded to gatifloxacin (95% 
with a 95% CI from 83% to 99%) and thirty-seven responded 
to outpatient therapy (92%, 95% CI from 80% to 98%). One 
of the three patients requiring hospital admission had a 
MASCC score 21. More recently, a randomised comparison 
was performed by Innes et al [25] in a single institution. The 
definition of low-risk was inspired from the Talcott model but 
the authors added extra criteria (like an underlying cancer 
being a solid tumor or a lymphoma or an anticipated short 
duration of neutropenia). The MASCC score was not avail-
able at the time the study was designed; a retrospective as-
sessment led to the conclusion that more than 95% of the 
included episodes were associated with a MASCC score 21 
but it can be anticipated that the study population was a re-
stricted group of patients with a score 21 due to the ex-
pected larger sensitivity of the MASCC score. One hundred 
and twenty-six episodes (occurring in 102 patients) were ran-
domised between in-hospital intravenous treatment with 
gentamicin and tazocin compared to an oral regimen with 
ciprofloxacin and amoxicillin-clavulanate and discharge as 
early as possible after 24 hours of hospitalisation. In the 
orally treated 66 episodes, the rate of discharge after 2 days 
was 55%. In both arms, the therapeutic results were excellent 
with the development of only one serious complication in each 
arm. From the economic perspective, the prospectively planned 
cost analysis revealed a reduction in the costs from a mean of 
£840 to £470. The mean nursing hours were also reduced (from 
21 hours to 11 hours). The authors concluded that the oral 
treatment combined with the early discharge was a safe cost-
effective alternative to conventional management but stressed 
that the results of the approach might be different when used 
outside a single specialist center and they argue about the 
necessity of conducting a larger multicentric trial. A survey 
performed by the same team among uK physicians showed 
that there was only little introduction of newer strategies for 
the management of low-risk febrile neutropenia, but that the 
willingness to perform that large study was high [26]. In 
other countries, there can be a larger introduction of adapted 
therapy according to risk assessment. A single institution study 
testing oral treatment (also ciprofloxacin and amoxicillin-
clavulanate) and discharge following 24 hours of in-hospital 
surveillance was conducted in one of the institutions having 
derived the MASCC score and using it as a tool for defining 
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(5), due to a reason not strictly linked to the infectious proc-
ess. All other low-risk patients were switched to oral therapy 
24 hours after defervescence and they were discharged home 
with oral treatment to be continued for 5 days. No mortality 
was observed in these discharged patients although 2 patients 
required readmission (one 2 days after discharge for fever 
recurrence and another much later due to development of 
fungal infection). The authors felt that the score was a useful 
tool for identifying low-risk haematological malignancies 
combined with initial intravenous therapy and in-hospital 
surveillance. They applied it in multiple episodes for the same 
patients even though no change was observed in their conclu-
sions when restricting the analysis on the first episodes only. 
Thirty-six patients who were treated with oral antibiotic 
therapy were asked to answer to a questionnaire of satisfaction 
and 94% stated their preference for oral antibiotic therapy in 
case of future low-risk febrile episode. In another, quite recent, 
study [29], the authors included 55 MASCC low-risk episodes 
(score 21) occurring in 54 patients whom they treated with 
oral moxifloxacin and G-CSF immediately in an outpatient 
setting. Additional criteria were used, related to patients’ 
ability to take oral medication or to the risk of complication 
(patients with acute leukaemia, transplant, chronic obstructive 
pulmonary disease, documented pneumonia, hypotension, 
signs of dehydration, elevated creatinine level or transami-
nases level were excluded). Treatment was successful in 50 
episodes (91%); 5 hospital admissions were required although 
only 1 patient developed a serious complication (septic shock 
due to a staphylococcus infection). No patient died while on 
the study. Another study with a larger sample size was con-
ducted by the EORTC Infectious Diseases Group testing the 
effectiveness of moxifloxacin in low-risk febrile neutropenic 
patients who were selected using the MASCC score. The 
comparison arm consisted of ciprofloxacin and amoxicillin-
clavulanate. Outpatient treatment and/or early discharge was 
planned in the protocol if additional criteria were met and 
one of the objectives of the study was to estimate under gen-
eral conditions and in the context of a multicentric, multina-
tional study, the proportion of patients with successful early 
discharge. Its findings are currently under analysis. An Italian 
study, from university La Sapienza in Rome, was performed 
in outpatients treated for an haematological malignancy. 
Patients were instructed to attend the haematological emer-
gency unit, in case of fever development. Their MASCC score 
was assessed and their management was organized according 
to a prediction of low-risk (score 21) or high-risk. All patients 
started on empiric treatment with intravenous ceftriaxone and 
amikacin. High-risk patients were managed fully in-hospital. 
Low-risk patients were planned to be discharged on oral ce-
fixime (or parenteral antibiotics or another oral therapy in 
case of failure of empiric regimen), after defervescence for 48 
hours and in the absence of deterioration of clinical status, 
regardless of their neutropenic status One hundred consecu-
tive episodes (87 outpatients) were included in the study, 90 
with a low-risk prediction and 10 with a high-risk prediction. 
In thirty-one episodes, the patients were not eligible for early 
discharge, because of prediction as high-risk at admission, 
clinical deterioration or patients’ refusal. In sixty-nine episodes, 
all with a baseline low-risk prediction, the patients were dis-
charged on oral cefixime (54 cases), on the initial parenteral 
regimen (14 cases) or on oral levofloxacin (1 case). Two re-
admissions were required but no serious complications oc-
curred. Once again, the authors stressed that risk prediction 
is a different issue from safe outpatient management and they 
believe this concept is particularly true in patients with hae-
matological malignancies.
C O N C l U D I N g  D I S C U S S I O N
There is no doubt that febrile neutropenia is a heterogene-
ous condition and that any accurate risk stratification system is 
a valuable tool in guiding the management of selected groups 
of patients. Furthermore, there are evidence-based data and 
reviews showing that oral treatment is a safe and feasible alter-
native to conventional intravenous therapy and the published 
scoring systems for predicting risk are sufficiently validated to 
guide patient selection for administration of oral treatment; 
in such cases a scoring system is adopted; the MASCC score 
should probably be preferred because of increased sensitivity 
at a low cost to positive predictive value. However, there is still 
room for improvement, especially in the population of patients 
with haematological malignancies. Further research should be 
conducted, particularly in the field of rapid laboratory tests 
[10] as most of the clinical data have been already studied 
and as the inclusion of variables considered to be associated 
to the duration of neutropenia (like the chemotherapy drugs, 
the interval from chemotherapy and onset of fever, …) failed 
to improve the discriminant value of the MASCC scoring 
system [30]. The issue of ambulatory treatment is more deli-
cate; indeed, the studies had more varying designs in terms 
of timing of discharge and we have few data from randomised 
studies. From most of the published reports, however, it can 
be concluded that an initial surveillance in-hospital might be 
extremely important for the safety of the management. In that 
context, the scoring systems remain a valuable tool but with 
additional criteria, at least those not linked to risk but related 
to patients’ expected compliance to treatment and to monitor-
ing measures as well as to home environment. The acceptable 
range of positive predictive values of scoring systems should 
probably be more restricted or additional criteria plausibly 
associated to risk might be considered. Further research 
should also be conducted looking at variables predictive of 
outcome but collected in the short term follow-up. Indeed, the 
usefulness of reassessment of the currently available scoring 
systems has not been sufficiently studied. They are probably 
HOSPITAL CHRONICLES 2(2), 2007
72
of marginal value as most of the variables included in them 
are not susceptible to change. Ambulatory oral treatment has 
been shown to be very effective and safe in strictly selected 
groups of patients compared to the total population of those 
predicted at low-risk. Increasing the ratio between patients 
predicted at low-risk and those effectively and safely discharged 
would certainly be the goal of further research.
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